Celyad (Belgium)

Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Jozef Bartúnek, André Terzic, Beth A. Davison et al. · European Heart Journal · 2016 · 180 citations · Full text

Benefit of Cardiopoietic Mesenchymal Stem Cell Therapy on Left Ventricular Remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Study

John R. Teerlink, Marco Metra, Gerasimos Filippatos et al. · European Journal of Heart Failure · 2017 · 109 citations · Full text

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Jean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer et al. · Journal of Thoracic Oncology · 2016 · 85 citations · Full text

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange et al. · The Lancet Haematology · 2023 · 83 citations · Full text

Hematological Malignancy, Cell Therapy, Dose Escalation Segment +11

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Trial Design

Jozef Bartúnek, Beth A. Davison, Warren Sherman et al. · European Journal of Heart Failure · 2015 · 82 citations · Full text